Dry-powder inhalers

Drug Delivery to the Lung

Volumn , Issue , 2001, Pages 421-448

  Borgström, Lars ^a,b   O’Callaghan, Chris ^c   Bisgaard, Hans ^d   Pedersen, Søren ^e,f  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057937388     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (93)

1. Bell J, Hartley P, Cox J. Dry powder aerosols I: A new powder inhalation device. J Pharm Sci 1971; 60:1559–1564.
2. Hetzel M, Clark T. Comparison of salbutamol Rotahaler with conventional pressurized aerosol. Clin Allergy 1977; 7:563–568.
3. Pover G, Langdon C, Jones S, Fidler C. Evaluation of a breath operated powder inhaler. J Int Med Res 1988; 16:201–203.
4. Wetterlin K. Turbuhaler: A new powder inhaler for administration of drugs to the airways. Pharm Res 1988; 5:506–508.
5. Brindley A, Sumby B, Smith I, Prime D, Haywood P, Grant A. Design, manufacture and dose consistency of the Serevent Diskus. Pharm Technol Eur 1995; 7:16–17, 20–22.
6. Crompton G. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis 1982; 63:101–104.
7. Borgström L, Bondesson E, Morén F, Trofast E, Newman S. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994; 7:69–73.
8. Zanen P, Go L, Lammers J-W. Optimal particle size for β2-agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996; 51:977–980.
9. Leach C. Enhanced drug delivery through reformulating MDIs with HFA propellants- drug deposition and its effect on preclinical and clinical programs. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, 1996:133–144.
10. Olsson B, Borgström L, Asking L, Bondesson E. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In: Dalby R, Byron P, Farr S, eds. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, 1996:273–281.
11. Sacohetti M, van Ort M. Spray-drying and supercritical fluid particle generation technique. In: Hickey AJ, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. Vol. 94. New York: Marcel Dekker, 1996:337–384.
12. Vidgren M, Vidgren P, Paronen T. Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate. Int J Pharm 1987; 35:139–144.
13. Staniforth J, Rees J, Lai F, Hersey J. Interparticle forces in binary and ternary ordered powder mixes. J Pharm Pharmacol 1982; 34:141–145.
14. Hersey J. Ordered mixing: A new concept in powder mixing practice. Powder Technol 1975; 11:41–44.
15. Kassem N, Ganderton D. The influence of carrier surface on the characteristics of inspirable powder aerosols. J Pharm Pharmacol 1990; 42:11P.
16. Zeng X, Martin G, Marriott C, Pritchard J. Effects of surface smoothness of lactose on the delivery of salbutamol sulphate from dry powder inhalers. Pharm Res 1997; 14:s136.
17. Asking L, Lööf T, Pettersson G. Flutide Diskus less consistent than Pulmicort Turbuhaler with respect to in vitro fine particle dose proportionality. Am J Respir Crit Care Med 2001: Accepted.
18. Rudt S, Müller R. In vitro phagocytosis assay of nano- and microparticles by chemiluminescence: I. Effect of analytical parameters, particle size and particle concentration. J Contr Rel 1992; 22:263–272.
19. Edwards D, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997; 276:1868.
20. de Boer AH, Winter HMI, Lerk CF. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers: Part I. Inhalation characteristics, work of breathing and volunteers’ preference in dependence of the inhaler resistance. Int J Pharm 1996; 130:231–244.
21. de Boer A, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers: Part2. Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm 1996; 138:45–56.
22. de Boer A, Bolhuis G, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 3: The effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200 Turbuhaler. Int J Pharm 1997; 153:67–77.
23. European Pharmacopoeia, Inhalanda. Vol. 2. Strasbourg: European Pharmacopoeia Secretariat, 1999:988.
24. Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med 1994; 7(Suppl 1): S43–S47.
25. Bisgaard H, Klug B, Sumby B, Burnell P. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998; 11:1111–1115.
26. Heinbecker P. A method for the demonstration of calibre changes in the bronchi in normal respiration. J Clin Invest 1927; 4:459–469.
27. McNeill R, Malcom G, Rhind Brown W. Acomparison of expiratory and inspiratory flow rates in health and in chronic pulmonary disease. Thorax 1959; 14:225–231.
28. Clark A, Hollingworth A. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers—implications for in vitro testing. J Aerosol Med 1993; 6:99–110.
29. Clark A. Effect of powder inhaler resistance upon inspiratory profiles in health and disease. In: Dalby R, Byron P, Farr S, eds. Respiratory Drug Delivery IV. Buffalo Grove, IL: Interpharm Press, 1994:117–123.
30. Assi K, Chrystyn H. The device resistance of recently introduced dry-powder inhalers. J Pharm Pharmacol 2000; 52:58.
31. Pedersen S, Hansen O, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65:308–310.
32. Pedersen S. How to use a Rotahaler. Arch Dis Child 1986; 61:11–14.
33. Newman S, Pavia D, Garland N, Clarke S. Effects of various inhalation modes on the deposition of radiactive pressurized aerosols. Eur J Respir Dis 1982; 63:57–65.
34. Dolovich M, Rhem R, Rashid F, Bowen B, Coates G, Hill M. Lung deposition of albuterol sulphate from the Dura Dryhaler in normal adults. Am J Respir Crit Care Med 1996; 153:A62.
35. Warren S, Taylor G, Godfrey C, Coté G, Hill M. Gamma scintigraphic evaluation of beclomethasone dipropionate (BDP) from the Spiros dry powder inhaler. J Aerosol Med 1999; 12:117.
36. Newman S, Pavia D, Clarke S. How should a pressurized beta-adrenergic bronchodilator be inhaled? Eur J Respir Dis 1981; 62:3–21.
37. Svartengren K, Lindestad P-Å, Svartengren M, Philipsson K, Bylin G, Camner P. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med 1995; 152:32–37.
38. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986; 41:118–124.
39. Liard R, Zurek M, Aubier M, Korobaeff M, Henry C, Neukirch F. Misuse of pressurized metered dose inhalers by asthmatic patients treated in French private practice. Rev Epidém et Santé1995; 43:242–249.
40. Agertoft L, Pedersen S. Importance of training for correct Tubuhaler use in preschool children. Acta Paediatr 1998; 87:842–847.
41. Pedersen S, Stefensen G. Fenoterol powder inhaler technique in children: Influence of inspiratory flow rate and breath-holding. Eur Respir Dis 1986; 68:207–214.
42. Nielsen K, Skov M, Klug B, Ifversen M, Bisgaard H. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. Eur Respir J 1997; 10:2105–2109.
43. Ståhl E, Ribeiro L, Sandahl G. Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler in children with mild to moderate asthma. Pediatr Pulmonol 1996; 22:106–110.
44. Nielsen K, Auk I, Bojsen K, Ifversen M, Klug B, Bisgaard H. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow rates in asthmatic children. Eur Respir J 1998; 11:350–354.
45. Brown P, Ning A, Greening A, McLean A, Crompton G. Peak inspiratory flow through Turbuhaler in acute asthma. Eur Respir J 1995; 8:1940–1941.
46. Nana A, Youngchaiyud P, Maranetra N, et al. β2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med 1998; 92:167–172.
47. Löfdahl C, Andersson L, Bondesson E, et al. Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction. Eur Respir J 1997; 10:2474–2478.
48. Tönnesen F, Laursen L, Evald T, Ståhl E, Ibsen T. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest 1994; 105:697–700.
49. Jackson L, Ståhl E, Holgate S. Terbutaline via pressurised metered dose inhaler (PMDI) and turbuhaler in highly reactive asthmatic patients. Eur Respir J 1994; 7:1598–1601.
50. Selroos O, Löfroos A-B, Pietinalho A, Riska H. Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma. Thorax 1994; 49:1228–1230.
51. Dolovich M, Vanziegelheim M, Hidinger K. Influence of inspiratory flow rate on the response to terbutaline sulphate inhaled via the Turbuhaler. Am Rev Respir Dis 1988; 137:433.
52. Engel T, Scharling B, Skovstedt B, Heining J. Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes. Br J Clin Pharmacol 1992; 33:439–444.
53. Newman S, Morén F, Trofast E, Talaee N, Clarke S. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm 1991; 74:209–213.
54. Dal Negro R, Pomari C, Micheletto C, Cantini L. Peak inspiratory flow rate as measured through a new powder inhaler, does not correlate with asthma severity or influence effect of inhaled salbutamol. Adv Ther 1997; 14:181–191.
55. Pitcaim G, Lunghetti G, Ventura P, Newman S. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates. Int J Pharm 1994; 102:11–18.
56. Groth S, Dirksen H. Optimal inhalation procedure for the fenoterol powder inhaler. Eur J Respir Dis 1983; 64:17–24.
57. Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm 1994; 102:127–132.
58. Richards R, Simpson S, Renwick A, Holgate S. Inhalation rate of sodium cromoglycate determines plasma pharmacokinetics and protection against AMP-induced bronchoconstriction in asthma. Eur Respir J 1988; 1:896–901.
59. Shaw M. Effective and reliable drug delivery. In: Jackson W, ed. Turbuhaler. Oxford, UK: Clinical Vision, 1999.
60. Asking L, Axelsson M, Lindberg J. Aluminium blisters may fail to protect against humidity. Drug Delivery to the Lungs IX. London: The Aerosol Society, 1998:84–87.
61. Dickens C, McAughey J, Knight D, Baker S. Factors affecting in vitro testing of inhalers. J Aerosol Med 1994; 7:193–196.
62. Jashnani R, Byron P, Dalby R. Testing of dry powder aerosol formulations in different environmental conditions. Int J Pharm 1995; 113:123–130.
63. Lindsay D, Russell N, Thompson J, Warnock T, Shellshear I, Buchanan P. A multicentre comparison of the efficacy of terbutaline Turbuhaler and salbutamol pressurized metered dose inhaler in hot, humid regions. Eur Respir J 1994; 7:342–345.
64. Bell J, Hartley P, Cox J. Dry powder aerosols: I. A new powder inhalation device. J Pharm Sci 1971; 60:1559–1564.
65. Steckel H, Müller B. In vitro evaluation of dry powder inhalers: II. influence of carrier particle size and concentration on in vitro deposition. Int J Pharm 1997; 154:31–37.
66. Rosenborg J, Larsson P, Luts A, et al. Lung deposition of formoterol was greater after inhalation via the dry powder inhaler (DPI) Turbuhaler than via the DPI Aerolizer. Eur Respir J 1999; 14:62s.
67. Warren S, Taylor G. Effect of inhalation flow profiles on the deposition of radiolabelled BDP from a novel dry powder inhaler (DPI, Clickhaler), a conventional metered dose inhaler (MDI) and MDI plus spacer. In: Dalby R, Byron P, Farr S, eds. Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998:453–455.
68. Vidgren M, Kärkkäinen A, Karjalainen P, Paronen P, Nuutinen J. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm 1988; 42:211–216.
69. Johnson M. Fluticasone propionate: pharmacokinetic and pharmacodynamic implications of different aerosol delivery systems. In: Dalby R, Byron P, Farr S, eds. Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998:61–70.
70. Thorsson L, Edsbäcker S. Lung deposition of budesonide via Turbuhaler was greater than that of fluticasone propionate via Diskus or pMDI. Am J Respir Crit Care Med 1999; 159:A118.
71. Melchor R, Biddiscombe M, Mak V, Short M, Spiro S. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48:506–511.
72. Biddiscombe M, Melchor R, Mak V, et al. The lung deposition of salbutamol, directly labelled with technetium-99m, delivered by pressurised metered dose and dry powder inhalers. Int J Pharm 1993; 91:111–121.
73. Vidgren M, Arppe J, Vidgren P, Vainio P, Silvasti M, Tukiainen H. Pulmonary deposition of 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose inhaler. STP Pharma Sci 1994; 4(1):29–32.
74. Vidgren M, Vidgren P, Hyvärinen L, Silvasti M, Tukiainen H. Deposition and clinical response of 99m Tc–labelled salbutamol inhaled from a novel multiple dose powder inhaler. Am Rev Respir Dis 1993; 147(suppl):A58.
75. Vidgren M, Paronen P, Vidgren P, Vaino P, Nuutinen J. Radiotracer evaluation of the deposition of drug particles inhaled from a new powder inhaler. Int J Pharm 1990; 64:1–6.
76. Newman S, Pitcairn G, Hirst P, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000; 16:178–183.
77. Pitcairn G, Lankinen T, Seppäla O-P, Newman S. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient’s inspiratory effort. J Aerosol Med 2000; 13:97–104.
78. Borgström L, Newman S, Weisz A, Morén F. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci 1992; 81:753–755.
79. Borgström L, Newman S. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or Turbuhaler. Int J Pharm 1993; 97:47–53.
80. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7:1839–1844.
81. Thorsson L, Kenyon C, Newman S, Borgström L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm 1998; 168:119–127.
82. Newman S, Morén F, Trofast E, Talaee N, Clarke S. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm 1991; 74:209–213.
83. Meijer R, van der Mark T, Aalders B, Postma D, Koëter G. Home assessment of peak inspiratory flow through the Turbuhaler in asthmatic patients. Thorax 1996; 51:433–434.
84. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153:1636–1640.
85. Santolicandro A, Di Mauro M, Storti S, et al. Lung deposition of budesonide inhaled through Turbuhaler in asthmatic patients before and after bronchodilatation. Am J Respir Crit Care Med 1994; 149(suppl):A220.
86. Harrison KS, Laube BL. Bronchodilator pretreatment improves aerosol deposition uniformity in HIV-positive patients who cough while inhaling aerosolized pentamidine. Chest 1994; 106:421–426.
87. Everard M, Devadason S, Macerlean C, et al. Drug delivery from Turbuhaler to children with CF. Am J Respir Crit Care Med 1996; 153:A70.
88. Wildhaber J, Devadason S, Wilson J, et al. Lung deposition of budesonide from Turbuhaler in asthmatic children. Eur J Pediatr 1998; 157:1017–1022.
89. Pauwels R, Newman S, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J 1997; 10:2127–2138.
90. Beckman O, Bondesson E, Asking L, Källén A, Borgström L. Intra- and interindividual variations in pulmonary deposition via Turbuhaler and a pMDI. J Aerosol Med 1996; 9:449.
91. Borgström L, Bengtsson T, Derom E, Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int J Pharm 2000; 193:227–230.
92. Borgström L. Local versus total systemic bioavailability as a means to compare different inhaled formulations of the same substance. J Aerosol Med 1998; 11:55–63.
93. Engel T. Patient-related side effects of CFC-propellants. J Aerosol Med 1991; 4:163–167.